We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Diabetic Neuropathy Topical Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00661063
Recruitment Status : Unknown
Verified April 2008 by Irmandade da Santa Casa de Misericordia de Sao Paulo.
Recruitment status was:  Not yet recruiting
First Posted : April 18, 2008
Last Update Posted : April 18, 2008
Information provided by:

Study Description
Brief Summary:
Comparative study of efficacy and safety of ketamine, clonidine, mixture of both and placebo in patients with diabetic neuropathic pain

Condition or disease Intervention/treatment Phase
Diabetic Neuropathy Pain Drug: ketamine Drug: vehicle gel Drug: ketamine + clonidine Drug: clonidine gel 1% Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Diabetic Neuropathic Pain Topical Treatment- Comparative Study
Study Start Date : April 2008
Estimated Primary Completion Date : April 2009
Estimated Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: K
drug - ketamine 1% gel
Drug: ketamine
ketamine 150 mcg/g bid
Placebo Comparator: P
vehicle gel
Drug: vehicle gel
bid - 12 weeks
Experimental: M
association of ketamine and clonidine gel
Drug: ketamine + clonidine
ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
Experimental: C
clonidine gel
Drug: clonidine gel 1%
bid 12 weeks

Outcome Measures

Primary Outcome Measures :
  1. pain evaluation by visual analogue scale [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. pain evaluation by amount of rescue medication required [ Time Frame: 12 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes Mellitus type I or II
  • Mono or polyneuropathy
  • Treatment with Tricyclic Antidepressant, Carbamazepine during 3 weeks at least
  • Preserved cognition

Exclusion Criteria:

  • Ulcerative or infection or vesicle lesion in pain site
  • Pregnancy
  • Breast feeding
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00661063

Contact: Judymara L Gozzani, investigator 55-11-3884-0865 gozzani@osite.com.br

Santa Casa de São Paulo Not yet recruiting
São Paulo, Brazil, 01277-900
Sponsors and Collaborators
Irmandade da Santa Casa de Misericordia de Sao Paulo
Principal Investigator: Judymara L Gozzani, Investigator Santa Casa de São Paulo
More Information

Responsible Party: Judymara Lauzi Gozzani PhD, ISCMSP
ClinicalTrials.gov Identifier: NCT00661063     History of Changes
Other Study ID Numbers: 042/2007
First Posted: April 18, 2008    Key Record Dates
Last Update Posted: April 18, 2008
Last Verified: April 2008

Keywords provided by Irmandade da Santa Casa de Misericordia de Sao Paulo:
neuropathic pain

Additional relevant MeSH terms:
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Autonomic Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents